Positive Interim Phase II Study Results in Severe and Critical COVID-19 Patients Announced

Enlivex Therapeutics Ltd. reported positive interim results of an investigator-initiated Phase II clinical trial evaluating Allocetra in treating severe and critical COVID-19 patients. Allocetra™ is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system’s own natural regulation mechanisms.

Prof. Vernon van Heerden, Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the prior Phase Ib and the current Phase II COVID-19 clinical trial stated in a press release, "Thirteen COVID-19 patients have been treated to date with Allocetra. The Phase II patients that have been discharged from the hospital are currently healthy."

"We believe that these compelling preliminary results have demonstrated safety and an indication of the efficacy of Allocetra in these complicated patients, highlighting the potential of Enlivex's product candidate to benefit severe and critical COVID-19 patients as well as others suffering from cytokine storms and organ dysfunctions across various clinical indications."